What is currently included:

1. **Philanthropic grants & charitable contributions to independent external organizations**, including grants made through the CSR office and the company foundation.
2. Grants globally to **third-party medical, scientific & patient organizations**. For improving patient care, not promotional. Mostly continuing education conferences for healthcare professionals, HIV science conferences, HIV associations. Also grants to **independent Patient Advocacy Groups/patient organizations**.

What is currently NOT included:

1. Payments to **healthcare professionals who speak on behalf the company about products** in a promotional sense.
2. **Political/lobbying contributions**.
3. **Technical Assistance/In-kind or donation of services**. Any support or product that is not a cash-based grant to an external organization. We do attempt to categorize/include examples of this within our qualitative questions to acknowledge the larger depth/scope of the response of the pharmaceutical industry.
4. **Patient access expenses**. In the context of registration, regulatory or pricing deals, not external monetary grants.